ALPMY News and Press, Astellas Pharma Inc. ADR From 01/20/23

Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) said the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial of its gene replacement therapy AT845 to treat adults with late-onset Pompe disease (LOPD). The FDA had placed a hold on the phase 1/2 t...

Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease PR Newswire TOKYO , Jan. 20, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasuka...

Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium PR Newswire Data shows investigational zolbetuximab reduced risk of progression or death by 24.9% Study evaluated patients with Claudin 18.2-positiv...

Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions PR Newswire TOKYO , Jan. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announce...

Selecta Biosciences ( NASDAQ: SELB ) stock rose ~10% on Monday after the company said it signed an exclusive licensing and development agreement with Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) for IdeXork (Xork). The companies noted that Xork is being st...

Twist Bioscience ( NASDAQ: TWST ) and Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) are collaborating to discover antibodies against multiple targets of interest to develop therapies for patients with diseases lacking treatment options. Under the agreement, Twist wi...

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease PR Newswire Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatme...

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...

Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer PR News...

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers PR Newswire Astellas' GLOW trial, the se...